SAN CARLOS, Calif. and WASHINGTON, Feb. 6, 2020 /PRNewswire/ -- ALK Positive (a patient-led group of 1,900+ lung cancer patients and caregivers in 50+ countries) and GO2 for Lung Cancer (a global lung cancer advocacy and education organization) are awarding a two-year, $500,000 Research Collaboration Grant to two renowned lung [...]
GO2 for Lung Cancer points to targeted treatments and early screenings SAN CARLOS, Calif. and WASHINGTON, Jan. 8, 2020 /PRNewswire/ -- Today's report concerning improvements in cancer mortality is welcomed news. The recently released Cancer Statistics 2020 report shows that the decline in lung cancer deaths [...]
SAN CARLOS, Calif. and WASHINGTON DC, December 12, 2019 – The Lung Cancer Registry has launched new surveys to do an even better job of capturing important moments in a patient’s lung cancer journey. These new surveys include questions [...]
On December 3, 2019, the U.S. Food and Drug Administration approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) as a first treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no [...]
SAN CARLOS, Calif., Dec. 3, 2019 -- GO2 for Lung Cancer announced the recipients of the 2019 Young Innovators Team Awards (YITA) today. Two teams of researchers received grants totaling $500,000 for their work developing novel strategies to treat KRAS-mutant non-small cell lung cancer (NSCLC) [...]
AstraZeneca Announced as 2019 "Simply the Best Award" Honoree SAN CARLOS, Calif. and WASHINGTON DC, November 12, 2019 – GO2 for Lung Cancer (a merger of the Bonnie J. Addario Lung Cancer Foundation and Lung Cancer Alliance) recognized AstraZeneca [...]
GO2 for Lung Cancer has partnered with Belong.Life to provide patient and caregiver support and education on the world’s largest social network for cancer patients. Within the GO2 Foundation membership area, our social workers, clinical trial specialists, and survivor-volunteers will [...]
On August 15, 2019 the U.S. Food and Drug Administration approved Rozlytrek (entrectinib) for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer. It was also simultaneously approved for the treatment of patients with any solid tumor [...]
GO2 for Lung Cancer is pleased to announce that it presented Solange Peters, MD, PhD, with the 2019 Bonnie J. Addario Lectureship Award for her emphasis on groundbreaking biomarker research, improving access to care for lung cancer patients worldwide, and [...]
On June 17, 2019, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior [...]